Article

Even Low Doses of Radiation Can Prompt Cancer Cell Growth

Author(s):

Investigators find that radiation equivalent to 3 CT scans prompts the growth of the p53 mutation in mice.

Even low doses of radiation have been shown to give cancer-capable cells an advantage over normal cells in

healthy

tissue, according to a new study.

A radiation dose equivalent to 3 CT scans, which is considered a safe amount, was found to increase the number of cells with a p53 mutation in mice, according to a new study conducted by the

Wellcome

Sanger Institute and the University of Cambridge. However, investigators found that giving the mice an antioxidant prior to radiation exposure

prompted

the growth of healthy cells. Those cells outnumbered, and even replaced cells, with the p53 mutation.

Investigators gave mice a 50

milligray

dose of radiation, which is equivalent to 3 or 4 CT scans, according to the study. Mice were then given the OTC antioxidant N-Acetyl Cysteine (NAC) and exposed them to the same levels of radiation. Although the antioxidant promoted the growth of healthy cells, it did not help them battle the mutated cells. This was effective in the esophagus and researchers don’t know how it would act in other tissue.

“Our bodies are the set of ‘Game of Clones,’ a continuous battle for space between normal and mutant cells,” the study’s first author from the

Wellcome

Sanger Institute, David Fernandez-Antoran

, MD, said in a press release. “We show that even low doses of radiation,

similar to

three CT scans’ worth, can weigh the odds in

favor

of cancer-capable mutant cells. We’ve uncovered an additional potential cancer risk as a result of radiation that needs to be recognized.”

According to the study, this may open another avenue for cancer

treatment

. Fit, healthy cells naturally push out cancer capable cells without any known toxic adverse effects.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards